Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SAR231893 (REGN668) DP1
SAR231893 DP1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SAR231893 (REGN668) Drug Product (DP) 1 | EXPERIMENTAL | SAR231893 (REGN668) Drug Product 1 in a single subcutaneous injection |
| SAR231893 (REGN668) Drug Product (DP) 2 | EXPERIMENTAL | SAR231893 (REGN668) Drug Product 2 in a single subcutaneous injection |
| Name | Type | Description |
|---|---|---|
| SAR231893 (REGN668) DP1 | BIOLOGICAL | Pharmaceutical form:solution Route of administration: subcutaneous |
| SAR231893 (REGN668) DP2 | BIOLOGICAL | Pharmaceutical form:solution Route of administration: subcutaneous |
Inclusion criteria: * Healthy male and female subjects between 18 and 45 years of age Exclusion criteria: * Presence or history of drug hypersensitivity or allergic disease * History or presence of dermatological disorders * Fever or persistent chronic or active recurring infection requiring trea...
SAR231893 DP1 is an investigational monoclonal antibody developed by Sanofi. It is a drug product form of SAR231893 (REGN668) that has been studied in a Phase 1 clinical trial in healthy adult volunteers. No therapeutic indication has been disclosed for this asset.
SAR231893 DP1 is being developed by Sanofi, which trades under the ticker SNY. The compound is also referred to as SAR231893 (REGN668) DP1, reflecting its origin as a SAR231893 (REGN668) drug product.
SAR231893 DP1 is in Phase 1 development. It is investigational and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed for this drug product.
SAR231893 DP1 has been evaluated in one completed Phase 1 trial, NCT01537640, titled Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects. The trial enrolled 30 healthy adult volunteers in the United States and used a randomized, double-blind, controlled design.
Yes. SAR231893 DP1 and SAR231893 (REGN668) DP1 refer to the same Sanofi drug product. The longer name identifies the underlying SAR231893 (REGN668) antibody, while DP1 denotes the specific drug product formulation studied in the Phase 1 pharmacokinetic comparison trial.
The completed Phase 1 trial NCT01537640 compared the pharmacokinetics and safety of two SAR231893 (REGN668) drug products in healthy subjects. It enrolled 30 participants aged 18 years and older, was randomized, double-blind, and controlled, and was conducted in the United States.